UY26595A1 - LOW DOSE USE USE FORMULATIONS - Google Patents
LOW DOSE USE USE FORMULATIONSInfo
- Publication number
- UY26595A1 UY26595A1 UY26595A UY26595A UY26595A1 UY 26595 A1 UY26595 A1 UY 26595A1 UY 26595 A UY26595 A UY 26595A UY 26595 A UY26595 A UY 26595A UY 26595 A1 UY26595 A1 UY 26595A1
- Authority
- UY
- Uruguay
- Prior art keywords
- low dose
- formulations
- entecavir
- hepatitis
- treatment
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a composiciones que contienen una dosis baja de entecavir administradas en una base diaria para tratar una infección y/o co-infecciones del virus de la hepatitis B. Se proporcionan formulaciones para la administración oral de un entecavir de dosis baja. Otras sustancias farmacéuticas activas pueden ser incluidas en la composición de entecavir o pueden ser administradas separadamente para el tratamiento de la infección del virus de la hepatitis B o para el tratamiento de pacientes co-infectadosThe present invention relates to compositions containing a low dose of entecavir administered on a daily basis to treat an infection and / or co-infections of the hepatitis B virus. Formulations for oral administration of a low dose entecavir are provided. Other pharmaceutical active substances can be included in the composition of entecavir or can be administered separately for the treatment of hepatitis B virus infection or for the treatment of co-infected patients.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18567200P | 2000-02-29 | 2000-02-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY26595A1 true UY26595A1 (en) | 2001-09-28 |
Family
ID=22681972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY26595A UY26595A1 (en) | 2000-02-29 | 2001-02-23 | LOW DOSE USE USE FORMULATIONS |
Country Status (4)
Country | Link |
---|---|
CN (5) | CN1310999A (en) |
HK (1) | HK1040196A1 (en) |
UY (1) | UY26595A1 (en) |
ZA (1) | ZA200205900B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1732944B (en) * | 2005-09-02 | 2013-05-08 | 海南中和药业有限公司 | Entecavir dispersible tablet and its preparation process |
CN1820744B (en) * | 2006-04-04 | 2011-01-26 | 中国人民解放军军事医学科学院毒物药物研究所 | Oseltamivir phosphate granula and its preparing method |
CN101244260B (en) * | 2007-02-14 | 2011-12-28 | 成都地奥九泓制药厂 | Combined medicament for treating chronic hepatitis B |
CN101371841A (en) * | 2007-08-23 | 2009-02-25 | 浙江医药股份有限公司新昌制药厂 | Crystallization type Entecavir formulation as well as preparation method and use thereof |
CN102578564A (en) * | 2011-11-01 | 2012-07-18 | 江苏江山制药有限公司 | Preparation method for rapid-disintegrating directly-pressed particle mannitol preparation |
CN102416003A (en) * | 2011-12-08 | 2012-04-18 | 南京优科生物医药有限公司 | Method for preparing entecavir tablets |
CN102552210B (en) * | 2012-01-10 | 2013-12-11 | 四川海思科制药有限公司 | Entecavir capsule and preparation method thereof |
KR101285008B1 (en) * | 2012-04-18 | 2013-07-10 | 제일약품주식회사 | A method for preparing oral formulation of low dose entecavir |
CA3225480A1 (en) * | 2015-02-01 | 2016-08-04 | Syros Pharmaceuticals, Inc. | High surface-area lyophilized compositions comprising arsenic for oral administration in patients |
CN112535736B (en) * | 2020-12-14 | 2023-08-29 | 石家庄四药有限公司 | Entecavir composition and preparation method thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4489026A (en) * | 1982-09-07 | 1984-12-18 | The Upjohn Company | Process for preparing solid unit dosage forms of ultra-low dose drugs |
US5206244A (en) * | 1990-10-18 | 1993-04-27 | E. R. Squibb & Sons, Inc. | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
PH30929A (en) * | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
-
2000
- 2000-08-29 CN CN 00126403 patent/CN1310999A/en active Pending
- 2000-08-29 CN CNA2008101492879A patent/CN101385732A/en active Pending
- 2000-08-29 CN CN2012101468842A patent/CN102772413A/en active Pending
- 2000-08-29 CN CN 200810170016 patent/CN101444511B/en not_active Expired - Lifetime
- 2000-08-29 CN CN 200510128719 patent/CN1813753B/en not_active Ceased
-
2001
- 2001-02-23 UY UY26595A patent/UY26595A1/en not_active IP Right Cessation
-
2002
- 2002-03-04 HK HK02101639.3A patent/HK1040196A1/en unknown
- 2002-07-23 ZA ZA200205900A patent/ZA200205900B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200205900B (en) | 2004-03-29 |
CN1310999A (en) | 2001-09-05 |
CN1813753A (en) | 2006-08-09 |
CN102772413A (en) | 2012-11-14 |
CN101444511A (en) | 2009-06-03 |
CN101385732A (en) | 2009-03-18 |
CN1813753B (en) | 2010-04-07 |
CN101444511B (en) | 2013-01-02 |
HK1040196A1 (en) | 2002-05-31 |
CN1813753C (en) |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0108435B8 (en) | formulation and use of low-dose entecavir | |
AR035927A1 (en) | LACTAMA COMPOUND (N) - ((S) -2-HIDROXI-3-METHYLBUTIRILE) -1- (L-ALANINIL) - (S) -1-AMINO-3-METHYL-4,5,6,7-TETRAHYDRO -2H-3-BENZAZEPIN-2-ONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCEDURE FOR THE INHIBITION OF THE B-AMYLOID PEPTIDE RELEASE AND / OR ITS SYNTHESIS THAT USES IT AND ITS USE FOR THE FABR | |
ATE269056T1 (en) | HIGHLY EFFECTIVE MEDICINAL COMPOSITIONS CONTAINING DIHYDROERGOTAMIN | |
CR8352A (en) | PHARMACEUTICAL FORMULATIONS, PROCEDURES AND DOSAGE GUIDELINES FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES | |
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
CU23468B7 (en) | DOSAGE FORM OF PRAMIPEXOL IN A SINGLE DAILY DOSE | |
CR6458A (en) | VALDECOXIB COMPOSITIONS | |
DE60115029D1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING CANNABIDIOL DERIVATIVES | |
BR0108730A (en) | System, device and method for administering a drug, mouthpiece of a drug delivery device, device for administering multiple unit doses of a drug, methods for preparing a drug delivery system and a drug formulation and for treatment of a patient who needs multiple doses of a drug, drug formulation and multiparticulates | |
AR012614A1 (en) | A PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT INTENDED FOR THE TREATMENT OF A SUSCEPTIBLE VIRAL INFECTION OF TREATMENT WITH ALPHA INTERFER, A METHOD FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, FOR THE MANUFACTURE OF A MEDICINE | |
HRP20030046B1 (en) | Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome | |
RU2007104774A (en) | COMBINATION OF ANTI-HIV REVERSE TRANSCRIPTASE AND PROTEASES INHIBITORS | |
WO2006044968A3 (en) | Combination therapy for treating viral infections | |
ES2721899T3 (en) | Pharmaceutical compositions comprising fentanyl for intranasal administration | |
ATE324886T1 (en) | SOLID MEDICINAL COMPOSITION CONTAINING 4'-CYANO-TRIFLUORO-3-(4-FLUOROPHENYLSULPHONYL) -2-HYDROXY- 2-METHYLPROPIONO- M TOLUIDIDE AND PVP | |
DE50203456D1 (en) | DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SUCH COMPOUNDS | |
UY26595A1 (en) | LOW DOSE USE USE FORMULATIONS | |
KR970061244A (en) | Pharmaceutical composition for treating dementia | |
AR035946A1 (en) | PHARMACEUTICAL COMPOSITIONS TO USE IN THE TREATMENT OF DISORDERS IN WOMEN PERIMENOPAUSIC, MENOPAUSIC OR POSMENOPAUSIC, AND USES OF SUCH COMPOSITIONS FOR THE PREPARATION OF MEDICINES | |
ES2175663T3 (en) | SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MILTEPHOSINE FOR ORAL ADMINISTRATION IN THE TREATMENT OF LESHMANIASIS. | |
BR0109747A (en) | Use of 5- (2-pyrazinyl) -4-methyl-1-2-dithiol-3-thione (oltipraz) as a medicine, pharmaceutical composition for the prevention and treatment of hepatic fibrosis progression, use of 5- (2- pyrazinyl) -4-methyl-1,2-dithiol-3-thione and method for the prevention and treatment of fibrosis progression and liver cirrhosis | |
HUP0003546A2 (en) | Compositions for administering taxanes orally to human patients | |
AR036877A1 (en) | PHARMACEUTICAL FORMULATION | |
AR014082A1 (en) | ORAL SERTRALINE CONCENTRATE | |
BR0009875A (en) | Use of n-acetylcysteine for the preparation of a drug suitable for intravenous administration to prevent oxidative load in patients who have undergone dialysis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
110 | Patent granted |
Effective date: 20141023 |
|
VENC | Patent expired |
Effective date: 20210223 |